Carlo Milandri

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Michele Reni, Stefano Cordio, Carlo Milandri et al. · The Lancet Oncology · 2005 · 274 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8

Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial

Daniela Cardinale, Fabio Ciceri, Roberto Latini et al. · European Journal of Cancer · 2018 · 224 citations

International Cardiooncology Society-one, Preventive Medicine, Cardiovascular Disease +9

The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015

Giovanni De Manzoni, Daniele Marrelli, Gian Luca Baiocchi et al. · Gastric Cancer · 2016 · 184 citations · Full text

Gastrointestinal Oncology, Medicine, Italian Research Group +10

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text